LifeHealthcare Group Limited (ASX:LHC) announces its results for the half year ending 31 December 2017.
LifeHealthcare delivered solid revenue growth and strong underlying earnings and NPATA growth for the period. Revenue growth of 9.3% (3.4% organic growth) on the prior comparable period to $67.4 million was achieved with underlying EBITDA growth of 9.9% to $9.8 million and underlying NPATA growth of 10.2% to $4.0 million.
There was an uplift in the gross margin percentage of 2.5% as a result of foreign exchange with the AUD to USD hedging rate improving and a change in product mix due to higher growth in implants than capital products relative to the prior comparable period.
For further information please download PDF attached:
Download this document